Therapy of Aspiration: Out-of-Hospital and In-Hospital-Acquired

Abstract

Therapeutic considerations for aspiration pneumonia prioritize the risk of multidrug-resistant organisms. This involves integrating microbiological insights with each patient's unique risk profile, including the location at the time of aspiration, and whether it occurred in or out of the hospital. Our understanding of the microbiology of aspiration pneumonia has also evolved, leading to a reassessment of anaerobic bacteria as the primary pathogens. Emerging research shows a predominance of aerobic pathogens, in both community and hospital-acquired cases. This shift challenges the routine use of broad-spectrum antibiotics targeting anaerobes, which can contribute to antibiotic resistance and complications such as Clostridium difficile infections—concerns that are especially relevant given the growing issue of antimicrobial resistance. Adopting a comprehensive, patient-specific approach that incorporates these insights can optimize antibiotic selection, improve treatment outcomes, and reduce the risk of resistance and adverse effects.

Keywords

aspiration pneumonia - community-acquired aspiration - in-hospital aspiration - chemical pneumonitis - antibiotic therapy

Publication History

Article published online:
25 October 2024

• References

• 1 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
• 2 Torres A, Niederman MS, Chastre J. et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50 (03) 1700582
• 3 Kalil AC, Metersky ML, Klompas M. et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
• 4 Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med 2019; 380 (07) 651-663
• 5 Pan D, Chung S, Nielsen E, Niederman MS. Aspiration pneumonia. Semin Respir Crit Care Med 2024; 45 (02) 237-245
• 6 Prina E, Ranzani OT, Polverino E. et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015; 12 (02) 153-160
• 7 Restrepo MI, Babu BL, Reyes LF. et al; GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018; 52 (02) 1701190
• 8 Hidron AI, Kourbatova EV, Halvosa JS. et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41 (02) 159-166
• 9 Aslam B, Wang W, Arshad MI. et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 2018; 11: 1645-1658
• 10 Bartlett JG, Gorbach SL. The triple threat of aspiration pneumonia. Chest 1975; 68 (04) 560-566
• 11 Cameron JL, Anderson RP, Zuidema GD. Aspiration pneumonia. A clinical and experimental review. J Surg Res 1967; 7 (01) 44-53
• 12 Fisk RL, Symes JF, Aldridge LL, Couves CM. The pathophysiology and experimental therapy of acid pneumonitis in ex vivo lungs. Chest 1970; 57 (04) 364-370
• 13 Warner MA, Warner ME, Weber JG. Clinical significance of pulmonary aspiration during the perioperative period. Anesthesiology 1993; 78 (01) 56-62
• 14 Mendelson CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obstet Gynecol 1946; 52: 191-205
• 15 Teabeaut II JR. Aspiration of gastric contents; an experimental study. Am J Pathol 1952; 28 (01) 51-67 . Accessed October 4, 2024 at: https://www.ncbi.nlm.nih.gov/pubmed/14885406
• 16 Cameron JL, Caldini P, Toung J-K, Zuidema GD. Aspiration pneumonia: physiologic data following experimental aspiration. Surgery 1972; 72 (02) 238-245
• 17 Reeves EP, Lu H, Jacobs HL. et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002; 416 (6878) 291-297
• 18 Davidson BA, Knight PR, Helinski JD, Nader ND, Shanley TP, Johnson KJ. The role of tumor necrosis factor-alpha in the pathogenesis of aspiration pneumonitis in rats. Anesthesiology 1999; 91 (02) 486-499
• 19 James CF, Modell JH, Gibbs CP, Kuck EJ, Ruiz BC. Pulmonary aspiration–effects of volume and pH in the rat. Anesth Analg 1984; 63 (07) 665-668 . Accessed October 4, 2024 at: https://journals.lww.com/anesthesia-analgesia/fulltext/1984/07000/pulmonary_aspiration_effects_of_volume_and_ph_in.7.aspx
• 20 Mier L, Dreyfuss D, Darchy B. et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993; 19 (05) 279-284
• 21 El-Solh AA, Pietrantoni C, Bhat A. et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003; 167 (12) 1650-1654
• 22 Gadsby NJ, Musher DM. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev 2022; 35 (04) e0001522
• 23 Ko RE, Min KH, Hong SB. et al; Korean HAP/VAP Study Group. Characteristics, management, and clinical outcomes of patients with hospital-acquired and ventilator-associated pneumonia: a multicenter cohort study in Korea. Tuberc Respir Dis (Seoul) 2021; 84 (04) 317-325
• 24 Marin-Corral J, Pascual-Guardia S, Amati F. et al; GLIMP Investigators. Aspiration risk factors, microbiology, and empiric antibiotics for patients hospitalized with community-acquired pneumonia. Chest 2021; 159 (01) 58-72
• 25 Pan D, Nielsen E, Chung S, Niederman MS. Management of pneumonia in the critically ill. Minerva Med 2023; 114 (05) 667-682
• 26 Ramirez JA, Musher DM, Evans SE. et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest 2020; 158 (05) 1896-1911
• 27 Aliberti S, Cilloniz C, Chalmers JD. et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 2013; 68 (11) 997-999
• 28 Popovich KJ, Hota B, Aroutcheva A. et al. Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients. Clin Infect Dis 2013; 56 (08) 1067-1074
• 29 Zervou FN, Zacharioudakis IM, Ziakas PD, Rich JD, Mylonakis E. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis. Clin Infect Dis 2014; 59 (09) 1302-1311
• 30 Bartlett JG, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. Am J Med 1974; 56 (02) 202-207
• 31 Lorber B, Swenson RM. Bacteriology of aspiration pneumonia. A prospective study of community- and hospital-acquired cases. Ann Intern Med 1974; 81 (03) 329-331
• 32 Bartlett JG, Rosenblatt JE, Finegold SM. Percutaneous transtracheal aspiration in the diagnosis of anaerobic pulmonary infection. Ann Intern Med 1973; 79 (04) 535-540
• 33 Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999; 115 (01) 178-183
• 34 Vedamurthy A, Rajendran I, Manian F. Things We Do for No Reason™: routine coverage of anaerobes in aspiration pneumonia. J Hosp Med 2020; 15 (12) 754-756
• 35 Marimón JM, Sorarrain A, Ercibengoa M, Azcue N, Alonso M, Vidaur L. Lung microbiome on admission in critically ill patients with acute bacterial and viral pneumonia. Sci Rep 2023; 13 (01) 17724
• 36 Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia 2020; 12: 11
• 37 Almirall J, Boixeda R, de la Torre MC, Torres A. Aspiration pneumonia: a renewed perspective and practical approach. Respir Med 2021; 185: 106485
• 38 Takayanagi N, Kagiyama N, Ishiguro T, Tokunaga D, Sugita Y. Etiology and outcome of community-acquired lung abscess. Respiration 2010; 80 (02) 98-105
• 39 Polverino E, Dambrava P, Cillóniz C. et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 2010; 65 (04) 354-359
• 40 Martin-Loeches I, Torres A, Nagavci B. et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J 2023; 61 (04) 2200735
• 41 García Vázquez E, Mensa J, Martínez JA. et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24 (03) 190-195
• 42 Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51 (11) 3977-3982
• 43 Martínez JA, Horcajada JP, Almela M. et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36 (04) 389-395
• 44 Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131 (02) 466-473
• 45 Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33 (01) 153-159
• 46 Martin-Loeches I, Lisboa T, Rodriguez A. et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36 (04) 612-620
• 47 Gattarello S, Borgatta B, Solé-Violán J. et al; Community-Acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators*. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013). Chest 2014; 146 (01) 22-31
• 48 Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A. et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2024; 12 (04) 294-304
• 49 Hasegawa S, Shiraishi A, Yaegashi M, Hosokawa N, Morimoto K, Mori T. Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults. J Comp Eff Res 2019; 8 (15) 1275-1284
• 50 Bai AD, Srivastava S, Digby GC, Girard V, Razak F, Verma AA. Anaerobic antibiotic coverage in aspiration pneumonia and the associated benefits and harms: a retrospective cohort study. Chest 2024; 166 (01) 39-48
• 51 Chanderraj R, Admon AJ, He Y. et al. Mortality of patients with sepsis administered piperacillin-tazobactam vs cefepime. JAMA Intern Med 2024; 184 (07) 769-777
• 52 Sun T, Sun L, Wang R. et al. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Chin Med J (Engl) 2014; 127 (07) 1201-1205
• 53 Oi I, Ito I, Tanabe N. et al. Cefepime vs. meropenem for moderate-to-severe pneumonia in patients at risk for aspiration: an open-label, randomized study. J Infect Chemother 2020; 26 (02) 181-187
• 54 Hamao N, Ito I, Konishi S. et al. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial. BMC Pulm Med 2020; 20 (01) 160
• 55 Wunderink RG, Mendelson MH, Somero MS. et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134 (06) 1200-1207
• 56 Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47 (09) 2756-2764
• 57 Garnacho-Montero J, Sa-Borges M, Sole-Violan J. et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35 (08) 1888-1895
• 58 Martínez JA, Cobos-Trigueros N, Soriano A. et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010; 54 (09) 3590-3596
• 59 Micek ST, Welch EC, Khan J. et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54 (05) 1742-1748
• 60 Micek ST, Reichley RM, Kollef MH. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore) 2011; 90 (06) 390-395
• 61 Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144 (06) 1759-1767
• 62 Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; 2015 (08) CD007577
• 63 Capellier G, Mockly H, Charpentier C. et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS ONE 2012; 7 (08) e41290
• 64 Kollef MH, Chastre J, Clavel M. et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16 (06) R218
• 65 Bouadma L, Luyt CE, Tubach F. et al; PRORATA Trial Group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375 (9713) 463-474
• 66 Kyriazopoulou E, Liaskou-Antoniou L, Adamis G. et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med 2021; 203 (02) 202-210
• 67 de Jong E, van Oers JA, Beishuizen A. et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16 (07) 819-827
• 68 Confalonieri M, Urbino R, Potena A. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171 (03) 242-248
• 69 Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 2013; 62 (03) 439-445
• 70 Torres A, Sibila O, Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
• 71 Dequin P-F, Meziani F, Quenot J-P. et al; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023; 388 (21) 1931-1941
• 72 Villar J, Ferrando C, Martínez D. et al; Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8 (03) 267-276
• 73 Dragan V, Wei Y, Elligsen M, Kiss A, Walker SAN, Leis JA. Prophylactic antimicrobial therapy for acute aspiration pneumonitis. Clin Infect Dis 2018; 67 (04) 513-518